Want $5,000 in Annual Dividend Income? Invest in These 3 Stocks
Whether you're saving for retirement, want to set aside money for travel, or just want to give yourself a raise, dividend stocks can help give you some extra income to accomplish those goals. Plus, by investing in quality stocks, you can also potentially profit from their rising share prices. If…#organonco #ogn #enbridge #dominionenergy #organon #merckco #singulair #mainlineandexpress #dominion (Source: Reuters: Health)
Source: Reuters: Health - June 29, 2023 Category: Consumer Health News Source Type: news
Merck Accused of Downplaying Evidence of Drug ’s Brain Impact Merck Accused of Downplaying Evidence of Drug ’s Brain Impact
An early magazine advertisement for Merck ’s breakthrough asthma and allergy medicine, Singulair, featured a happy child, hanging upside-down from a tree.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - June 27, 2023 Category: Allergy & Immunology Tags: Pediatrics News Source Type: news
Merck downplayed severe psychological side-effects of its blockbuster children's asthma drug
A slew of lawsuits against Merck alleges the company covered up links between its asthma drug Singulair and severe effects on mental health, even causing suicide in at least 82 cases. (Source: the Mail online | Health)
Source: the Mail online | Health - June 26, 2023 Category: Consumer Health News Source Type: news
Novateur Ventures explores new strategy to reduce hyperinflammatory response caused by COVID-19
(PR Associates) Novateur's research proposes simple treatment paradigm using two generic drugs, directed to blocking inflammation in airways of patients with asthma, to target hyper-inflammatory response insevere COVID-19. This will be accomplished by combination of leukotriene biosynthesis blocker zileuton (Zyflo ® controlled release formulation) and inhibitor of cysteinyl leukotriene 1 receptor montelukast (Singulair ® ). Both these agents have been on market for many years, and their activity and side effects in humans are well known. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 12, 2020 Category: Infectious Diseases Source Type: news
FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis
Listen to FDA Drug Safety Pocast on strengthened existing warnings about serious behavior and mood-related changes with montelukast (brand name Singulair), a prescription medicine for asthma and allergy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 11, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA: Singulair to Get ‘ Black Box ’ Warning
Drug has long carried warning of potentially dangerous neuropsychiatric side effects (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 6, 2020 Category: Respiratory Medicine Tags: Family Medicine, Neurology, Nursing, Pediatrics, Pharmacy, Psychiatry, Pulmonology, Allergy, Emergency Medicine, Institutional, Source Type: news
FDA: Singulair to Get'Black Box' Warning
THURSDAY, March 5, 2020 -- Asthma and allergy drug montelukast -- sold as a generic and under the brand name Singulair -- will get a " boxed warning " over potential ties to neuropsychiatric effects, the U.S. Food and Drug Administration announced... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 5, 2020 Category: Pharmaceuticals Source Type: news
FDA requires boxed warning for asthma and allergy drug due to neuropsychiatric events
The US Food and Drug Administration announced Wednesday it is requiring a boxed warning -- the agency's most prominent warning -- for the asthma and allergy medication montelukast, sold under the brand name Singulair. (Source: CNN.com - Health)
Source: CNN.com - Health - March 5, 2020 Category: Consumer Health News Source Type: news
Allergy Med Singulair to Get'Black Box' Warning Over Psych Side Effects: FDA
Title: Allergy Med Singulair to Get ' Black Box ' Warning Over Psych Side Effects: FDACategory: Health NewsCreated: 3/4/2020 12:00:00 AMLast Editorial Review: 3/5/2020 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - March 5, 2020 Category: Allergy & Immunology Source Type: news
Allergy Med Singulair to Get 'Black Box' Warning Over Psych Side Effects: FDA
Title: Allergy Med Singulair to Get 'Black Box' Warning Over Psych Side Effects: FDACategory: Health NewsCreated: 3/4/2020 12:00:00 AMLast Editorial Review: 3/5/2020 12:00:00 AM (Source: MedicineNet Allergies General)
Source: MedicineNet Allergies General - March 5, 2020 Category: Allergy & Immunology Source Type: news
Allergy Med Singulair to Get ‘ Black Box ’ Warning Over Psych Side Effects: FDA
(Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - March 4, 2020 Category: Psychiatry Tags: Pharmacy, Psychiatry, Asthma, Allergy, News, Source Type: news
Singulair (montelukast) and All Montelukast Generics: Strengthened Boxed Warning - Due to Restricting Use for Allergic Rhinitis
FDA is strengthening existing warnings about serious behavior and mood-related changes with montelukast (Singulair and generics), which is a prescription medicine for asthma and allergy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 4, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis
FDA requires a Boxed Warning about serious mental health side effects for the asthma& allergy drug Singulair (montelukast). Only take montelukast for hay fever if other medicines do not work or cannot be tolerated. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 4, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Allergy Med Singulair to Get'Black Box' Warning Over Psych Side Effects: FDA
WEDNESDAY, March 4, 2020 -- Asthma and allergy drug montelukast -- sold as a generic and under the brand name Singulair -- will get a " boxed warning " over potential ties to neuropsychiatric effects, the U.S. Food and Drug Administration announced on... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 4, 2020 Category: General Medicine Source Type: news
Drug Safety Update: montelukast (Singulair) - reminder of the risk of neuropsychiatric reactions
The Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update highlights new and updated advice. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - September 24, 2019 Category: Drugs & Pharmacology Source Type: news
